

Non Renounceable Rights Issue – Appendix 3B Notice

Friday, 18 October 2019 - CCP Technologies Limited is pleased to announce a one for one non renounceable pro rata entitlement issue (**Right Issue**). In addition, one free attaching option (**Option**) for each share applied for will be granted. The Rights Issue will be available to holders of Shares in the Company with a registered address in Australia and New Zealand (**Eligible Shareholders**) as at Thursday 24 October 2019 (**Record Date**).

The Rights Issue is partially underwritten by two underwriters who have executed underwriting agreements to underwrite up to \$2,000,000.

Under the Rights Issue, the Company will issue 486,669,260 Fully Paid Ordinary Shares in the Company at an issue price of \$0.007 per new Share with one free attaching option per new Share.

The Company will raise up to \$3.4 million (before costs) under the Rights Issue.

The Offer will be made pursuant to a transaction specific prospectus in accordance with Section 713 of the Corporations Act (**Prospectus**) (available at www.asx.com.au and <https://www.ccp-technologies.com>). Accordingly, the Prospectus will be lodged with the Australian Securities & Investments Commission. Typically, rights issues do not require a prospectus where the conditions of Section 708AA of the Corporations Act apply. However, the issue of the free attaching option does not fall within the ambit of Section 708AA of the Corporations Act and, accordingly, a prospectus is required.

The Prospectus sets out the full details of the Offer. A copy of the Prospectus, together with a personalised entitlement and acceptance forms, will be despatched to eligible shareholders in accordance with the timetable below.

Eligible shareholders should review the Prospectus and seek advice before deciding to participate in the Rights Issue.

Moneys raised under the Right Issue will be utilised as follows:

- Marketing and business development;
- Ongoing development of the product suite;
- Provisioning for potential acquisitions;
- Meeting the expenses of the Entitlement Offer; and
- General working capital.

The number of Fully Paid Ordinary Shares on issue (after allowing for Shares pending cancellation) is 486,669,260.

Total number of new Shares to be issued under the Rights Issue is 486,669,260.

If fully subscribed, the total number of Shares on issue following completion of the Rights Issue will be 973,338,520.

Proposed Timetable

Event	Date
1.1 Announcement of Issue (prior to commencement of trading)	Friday 18 October 2019 (prior to commencement of trading)
1.2 Application to ASX for official quotation of the new Shares (prior to commencement of trading)	Friday 18 October 2019 (prior to commencement of trading)
1.3 Lodgement of Prospectus with ASX (prior to commencement of trading)	Friday 18 October 2019 (prior to commencement of trading)
1.4 Despatch of notice to shareholders informing them of the Rights Issue and notify ASX of despatch	Tuesday 22 October 2019
1.5 “Ex” Date (i.e date from which securities commence trading without the entitled to participate in the Rights Issue)	Wednesday 23 October 2019
1.6 Record Date (i.e. date for determining entitlement to participate in the Rights Issue)	Thursday 24 October 2019
1.7 Prospectus and Entitlement and Acceptance Forms will be despatched to eligible holders	Monday 28 October 2019 *
1.8 Closing Date for acceptance and payment of \$0.007 cents per new share (5:00pm AEST)	Thursday 7 November 2019
1.9 Trading commences on a deferred settlement basis	Friday 8 November 2019
1.10 Notify ASX of shortfall	Tuesday 12 November 2019
1.11 Statements for new Shares despatched	Thursday 14 November 2019
1.12 Trading of new Shares expected to commence	Friday 15 November 2019

** Last date to extend is 3 business days before the Closing Date.*

This timetable is indicative and subject to change in consultation with ASX.

The Directors reserve the right not to proceed with the Rights Issue, in which case any application money received will be refunded.

Actions required by Eligible Shareholder

As an Eligible Shareholder, you may:

- (a) Take up your entitlement in full;
- (b) Take up part of your entitlement; or
- (c) Do nothing and allow your entitlement to lapse

Further details on how to perform any of the above actions are specified in Section 4.3 and 4.4 of the Prospectus.

If you have any queries in relation to the Rights Issue please contact Adam Gallagher at info@ccp-technologies.com or 1800 100 227

For further information please contact: enquiries@ccp-technologies.com

About CCP Technologies

CCP Technologies Limited offers an IoT technology solution suite and a device and software development services business.

The solution suite currently comprises a monitoring and reporting platform for temperature, movement and other ambient conditions, that is primarily applied to refrigerated biological material – food, medicines and research specimens.

The Company's IT development division specialises in IoT software and hardware development and maintenance and can deliver an end-to-end service for IoT innovators and managers that is a unique outsource offering in the marketplace.

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

CCP TECHNOLOGIES LIMITED (ASX: CT1)

ABN

58 009 213 754

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|---|
| 1 | +Class of +securities issued or to be issued | <div style="display: flex; justify-content: space-between;"><div>a) Ordinary Shares</div><div>b) Unlisted Options</div></div> |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | <div style="display: flex; justify-content: space-between;"><div>a) Up to 486,669,260 ordinary fully paid shares under a 1 for 1 partially underwritten non-renounceable entitlement offer (NREO) to Eligible Shareholders as detailed in announcement of 18 October 2019.</div><div>b) Up to 486,669,260 unlisted options attaching to each new share issued under NREO.</div></div> |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <div style="display: flex; justify-content: space-between;"><div>a) Pari Passu with existing Ordinary Fully Paid Shares.</div><div>b) Exercisable at \$0.015 each and expire 3 years from date of issue.</div></div> |

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

4 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	a) Yes b) Upon exercise to ordinary fully paid shares.
5 Issue price or consideration	a) \$0.007 per share b) Nil consideration as free attaching to shares.
6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To fund marketing & business development; ongoing development of the product suite; provision for potential acquisitions and general working capital requirements, including NREO costs as detailed in the announcement on 18 October 2019
6 Is the entity an ⁺eligible entity that has a obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the subject of this Appendix 3B</i>, and comply with section 6i	Yes
6 The date the security holder resolution under b rule 7.1A was passed	26 November 2018

⁺ See chapter 19 for defined terms.

6c	Number of +securities issued without security holder approval under rule 7.1	N/A
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of securities issued under an exception in rule 7.2	486,669,260 ordinary shares under NREO 486,669,260 unlisted options under NREO
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

7	Dates of entering ⁺ securities into uncertificated holdings or despatch of certificates	14 November 2019
---	--	------------------

8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)	Number	⁺ Class
		509,841,419	Ordinary Shares (CT1) as at date of this notice
		486,669,260	Ordinary Shares (CT1) under NREO
		996,510,679	Estimated Total Ordinary Shares (CT1) on Issue after NREO

9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	Number	+Class			
		Amount	Exercise Price	Expiration Date	ASX Code	
		4,000,000	Unlisted options vesting on 15 December 2018 and expiring on 15 December 2020 with an exercise price of \$0.10 per option			
		1,533,000	Unlisted options vesting on 15 December 2017 and expiring on 15 December 2019 with an exercise price of \$nil per option			
		1,446,550	Unlisted options vesting on 21 November 2019 and expiring on 20 November 2021 with an exercise price of \$0.10 per option			
		43,062,350	Unlisted options vesting on 7 December 2018 and expiring on 06 December 2020 with an exercise price of \$0.030 per option			
		486,669,260	Unlisted options expiring 3 years from date of issue with an exercise price of \$0.015 per option.			
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)					
		Unchanged				

⁺ See chapter 19 for defined terms.

--	--	--

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-renounceable
13	Ratio in which the ⁺ securities will be offered	1 for 1
14	⁺ Class of ⁺ securities to which the offer relates	Ordinary Shares
15	⁺ Record date to determine entitlements	24 October 2019
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Fractional entitlements will be rounded up to the nearest whole number.
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	All countries except Australia and New Zealand
19	Closing date for receipt of acceptances or renunciations	7 November 2019

⁺ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

20	Names of any underwriters	ZZL Pty Ltd as trustee for ZZL Family Trust & Nominees MRGL Pty Ltd as trustee for the Mr Gloss Unit Trust
21	Amount of any underwriting fee or commission	6% of the amount underwritten
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺ security holders	N/A
25	If the issue is contingent on ⁺ security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	On or around 28 October 2019
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A

⁺ See chapter 19 for defined terms.

- | | | |
|----|--|------------------|
| 30 | How do ⁺ security holders sell their entitlements <i>in full</i> through a broker? | N/A |
| 31 | How do ⁺ security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |
| 32 | How do ⁺ security holders dispose of their entitlements (except by sale through a broker)? | N/A |
| 33 | ⁺ Despatch date | 14 November 2019 |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities
(tick one)
- (a) ☐ Securities described in Part 1
- (b) ☐ All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 ☐ If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 ☐ If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
 1 - 1,000
 1,001 - 5,000
 5,001 - 10,000
 10,001 - 100,000
 100,001 and over
- 37 ☐ A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

⁺ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

38	Number of securities for which +quotation is sought					
39	Class of +securities for which quotation is sought					
40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment					
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)					
42	Number and +class of all +securities quoted on ASX (<i>including</i> the securities in clause 38)	<table border="1" style="width: 100%; border-collapse: collapse;"><thead><tr><th style="padding: 5px;">Number</th><th style="padding: 5px;">+Class</th></tr></thead><tbody><tr><td style="height: 80px;"></td><td style="height: 80px;"></td></tr></tbody></table>	Number	+Class		
Number	+Class					

+ See chapter 19 for defined terms.

Quotation agreement

- 1 ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those ⁺securities should not be granted ⁺quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any ⁺securities to be quoted and that no-one has any right to return any ⁺securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the ⁺securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Date: 18 October 2019

Joint Company Secretary

Print name:

Adam Gallagher

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	394,166,170
Add the following: - Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 - Number of fully paid ordinary securities issued in that 12 month period with shareholder approval - Number of partly paid ordinary securities that became fully paid in that 12 month period Note: - Include only ordinary securities here – other classes of equity securities cannot be added - Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed - It may be useful to set out issues of securities on different dates as separate line items	36,139,748 15,651,969
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-
“A”	445,957,887

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	66,893,683
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 Note: • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i>	63,883,532
“C”	63,883,532
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	66,893,683
Subtract “C” <i>Note: number must be same as shown in Step 3</i>	63,883,532
Total [“A” x 0.15] – “C”	3,010,151

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	445,957,887
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	44,595,789
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items	-
“E”	-

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	44,595,789
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	-
Total [“A” x 0.10] – “E”	44,595,789 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.